The San Francisco Vaccine and Prevention Unit (SFVPU) provides scientific leadership, capacity to recruit study volunteers into vaccine and non-vaccine prevention trials, innovative methods for community engagement in research, and mentorship of junior investigators. We will test vaccine and prevention strategies likely to have the greatest impact in reducing HIV infection in the United States and globally through our affiliation with the HIV Vaccine Trials Network and the HIV Prevention Trials Network. The SFVPU is housed in the San Francisco Department of Public Health, using a non-profit fiscal pass-through agency, Public Health Foundation Enterprises, to provide fiscal and human-resource management.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
5UM1AI069496-07
Application #
8415883
Study Section
Special Emphasis Panel (ZAI1-AR-A (M1))
Program Officer
Germuga, Donna E
Project Start
2007-03-02
Project End
2013-12-09
Budget Start
2013-01-01
Budget End
2013-12-09
Support Year
7
Fiscal Year
2013
Total Cost
$2,287,238
Indirect Cost
$192,769
Name
Public Health Foundation Enterprises
Department
Type
DUNS #
082199324
City
City of Industry
State
CA
Country
United States
Zip Code
91746
Kadede, Kevin; Ruel, Theodore; Kabami, Jane et al. (2016) Increased adolescent HIV testing with a hybrid mobile strategy in Uganda and Kenya. AIDS 30:2121-6
Godfrey, Catherine; Tauscher, Gail; Hunsberger, Sally et al. (2016) A survey of tuberculosis infection control practices at the NIH/NIAID/DAIDS-supported clinical trial sites in low and middle income countries. BMC Infect Dis 16:269
Huang, Ying; DiazGranados, Carlos; Janes, Holly et al. (2016) Selection of HIV vaccine candidates for concurrent testing in an efficacy trial. Curr Opin Virol 17:57-65
Lee, Sulggi A; Mefford, Joel A; Huang, Yong et al. (2016) Host genetic predictors of the kynurenine pathway of tryptophan catabolism among treated HIV-infected Ugandans. AIDS 30:1807-15
Cohen, Myron S; Chen, Ying Q; McCauley, Marybeth et al. (2016) Antiretroviral Therapy for the Prevention of HIV-1 Transmission. N Engl J Med 375:830-9
Saharia, Kapil K; Petrovas, Constantinos; Ferrando-Martinez, Sara et al. (2016) Tuberculosis Therapy Modifies the Cytokine Profile, Maturation State, and Expression of Inhibitory Molecules on Mycobacterium tuberculosis-Specific CD4+ T-Cells. PLoS One 11:e0158262
Nelson, LaRon E; Wilton, Leo; Moineddin, Rahim et al. (2016) Economic, Legal, and Social Hardships Associated with HIV Risk among Black Men who have Sex with Men in Six US Cities. J Urban Health 93:170-88
Zheng, Jia-Hua; Rower, Caitlin; McAllister, Kevin et al. (2016) Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spots. J Pharm Biomed Anal 122:16-20
Landovitz, Raphael J; Tran, Thuy Tien T; Cohn, Susan E et al. (2016) HIV Transmission Risk Behavior in a Cohort of HIV-Infected Treatment-Naïve Men and Women in the United States. AIDS Behav 20:2983-2995
Glidden, David V; Amico, K Rivet; Liu, Albert Y et al. (2016) Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension. Clin Infect Dis 62:1172-7

Showing the most recent 10 out of 92 publications